Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 3Unknown 1Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

NET 3Endocrine 3Thoracic 1Gynecologic 1Gastrointestinal 1

Conditions

Lymphoma 161Leukemia 99Lymphoma, Large B-Cell, Diffuse 94Precursor Cell Lymphoblastic Leukemia-Lymphoma 92Lymphoma, Non-Hodgkin 91Leukemia, Myeloid, Acute 76Hodgkin Disease 73Lymphoma, Follicular 63Burkitt Lymphoma 60Lymphoma, Mantle-Cell 56Lymphoma, Large-Cell, Immunoblastic 55Small Cell Lung Carcinoma 46Leukemia, Lymphocytic, Chronic, B-Cell 42Lung Neoplasms 41Neuroblastoma 40Lymphoma, B-Cell, Marginal Zone 33Congenital Abnormalities 33Multiple Myeloma 30Recurrence 27Sarcoma 26Central Nervous System Neoplasms 26Carcinoma, Non-Small-Cell Lung 25Myelodysplastic Syndromes 24Leukemia, Myelomonocytic, Acute 24Leukemia, Monocytic, Acute 24Leukemia, Erythroblastic, Acute 24Testicular Neoplasms 22Lymphoma, Large-Cell, Anaplastic 22Leukemia, Megakaryoblastic, Acute 22Brain Neoplasms 22

Interventions

Everolimus 17lutetium Lu 177 dotatate 7Octreotide 7pasireotide 6lanreotide 6gallium Ga 68 dotatate 5Temozolomide 5Sunitinib 5Positron Emission Tomography Computed Tomography 5surufatinib 4pembrolizumab 4Sorafenib 4Data Collection 4Carboplatin 43-Iodobenzylguanidine 4Positron-Emission Tomography 3Nivolumab 3Etoposide 3Capecitabine 390Y-octreotide, DOTA-Tyr(3)- 3pentetreotide 2pazopanib 2lenvatinib 2fosbretabulin 2fluorodopa F 18 2cabozantinib 2avelumab 2arginyllysine 2Single Photon Emission Computed Tomography Computed Tomography 2Pemetrexed 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Neuroendocrine Tumors × Etoposide × Clear all
NCT02402920 2026-03-10

Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer

M.D. Anderson Cancer Center

Phase 1 Completed
83 enrolled 13 charts
EndocrineNET

Neuroendocrine Tumors

NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

NCT03980925 2025-01-13

Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
37 enrolled 25 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡